Print

HVTN 702

Trial Details:

III Ongoing
NIH, HVTN, South African Medical Research Council, Pox-Protein Public-Private Partnership, GSK, Sanofi, BMGF November 15, 2016
ALVAC-HIV-C (vCP2438), Bivalent Subtype C gp120/MF59 Canarypox Env gp120 C, gp41 B, gag B, protease B; Protein Env C
ALVAC-HIV-C (vCP2438) Viral Vector - Pox
Bivalent Subtype C gp120/MF59 Protein
MF59
South Africa 5,400
NCT02968849
https://www.clinicaltrials.gov/ct2/show/NCT02968849